Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment
作者:Galina F. Makhaeva、Sofya V. Lushchekina、Nadezhda V. Kovaleva、Tatiana Yu. Astakhova、Natalia P. Boltneva、Elena V. Rudakova、Olga G. Serebryakova、Alexey N. Proshin、Igor V. Serkov、Tatiana P. Trofimova、Victor A. Tafeenko、Eugene V. Radchenko、Vladimir A. Palyulin、Vladimir P. Fisenko、Jan Korábečný、Ondrej Soukup、Rudy J. Richardson
DOI:10.1016/j.bioorg.2021.104974
日期:2021.7
synthesized eleven new amiridine-piperazine hybrids 5a-j and 7 as potential multifunctional agents for Alzheimer's disease (AD) treatment by reacting N-chloroacetylamiridine with piperazines. The compounds displayed mixed-type reversible inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Conjugates were moderate inhibitors of equine and human BChE with negligible fluctuation in anti-BChE
我们通过 N-氯乙酰脒与哌嗪反应合成了 11 种新的脒-哌嗪杂化物 5a-j 和 7,作为治疗阿尔茨海默病 (AD) 的潜在多功能药物。这些化合物表现出对乙酰胆碱酯酶 (AChE) 和丁酰胆碱酯酶 (BChE) 的混合型可逆抑制。偶联物是马和人 BChE 的中度抑制剂,抗 BChE 活性的波动可以忽略不计,而抗 AChE 活性基本上依赖于哌嗪环的 N4 取代。具有对位取代芳族部分(5g、5h 和双脒苷 7)的化合物在低微摩尔范围内具有最高的抗 AChE 活性。排名靠前的化合物 5h,N-(2,3,5,6,7,8-六氢-1H-环戊二烯[b]喹啉-9-基)-2-[4-(4-硝基-苯基)-哌嗪-1-基]-乙酰胺,AChE 的 IC50 = 1.83 ± 0.03 μM (Ki = 1.50 ± 0. 12 和 αKi = 2.58 ± 0.23 μM)。缀合物对羧酸酯酶的活性较低,表明在临床使用